Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Marietta, Georgia

4 studies are recruiting for non-small cell lung cancer (nsclc) in Marietta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with resp…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106), Marietta, Georgia
    Locations
    220 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06170788 on ClinicalTrials.gov

  2. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia
    Locations
    259 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07361497 on ClinicalTrials.gov

  3. A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

    The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia
    Locations
    279 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07361510 on ClinicalTrials.gov

  4. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Marietta, Georgia
    Locations
    206 in total
    Run by
    AstraZeneca

    See if you can join NCT07291037 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.